Mark Chin is listed as a director on 6 SEC Form D filings by 3 issuers between Jan 2018 and May 2023: Ensoma, Inc. (Boston, MA — biotechnology — 2023; $129M reported sold to 22 investors), Enliven Therapeutics, Inc. (Boulder, CO — pharmaceuticals — 2019; $90M reported sold to 20 investors) and Aura Biosciences, Inc. (Cambridge, MA — biotechnology — 2018–2019; $80.5M reported sold to 42 investors).
What this means A repeat sponsor — 3 separate companies raised money with this person listed as director, over about 5 years. Across those companies the filings report $299.5M sold in total.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, LA, ME, MO, MS, MT, NASAA, NC, NH, NM, OR, RI, TX, WA) — 2 bankruptcy cases matching the name listed in Key records below.
What this means 2 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 6 public filings for Mark Chin and found 9 differences: Form D filed 17 days after the first sale; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.